| Name | Title | Contact Details |
|---|---|---|
Jamie Kitano |
Director, Corporate Counsel | Profile |
Christopher Thompson |
SR VP Sales, Access, Govt Affairs | Profile |
Chris Slavinsky |
Chief Business and Legal Officer | Profile |
Thomas Fitzpatrick |
Chief Legal Officer | Profile |
Tizona Therapeutics, Inc. is a preclinical stage biotechnology company that is developing multiple, innovative immuno-oncology therapies. Tizona Therapeutics, Inc. was founded by MPM Capital and leading scientists from Dana Farber Cancer Institute, the University of Pittsburgh, Johns Hopkins, Memorial Sloan Kettering Cancer Center, and Brigham and Women`s Hospital.
Emerald Health Therapeutics is a Health Canada Licensed Producer of medical cannabis. A vertically integrated, seed-to-sale enterprise, Emerald has combined core competencies from decades of experience in pharmaceutical innovation with large-scale agriculture expertise. Our ambition is to be at the forefront of developing knowledge and products that provide wellness and health benefits from cannabis.
General Automation Lab Technologies (GALT), a San Francisco-based life science company, is developing advanced products to help researchers and companies cultivate and study bacteria and other microbes.
NexImmune is an emerging biopharmaceutical company advancing a new generation of immunotherapies based on our proprietary AIM™ technology.
Syndax is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple-negative breast cancer (TNBC). Entinostat is an oral, small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body`s immune response to tumors. Entinostat is being evaluated as a combination therapeutic in Phase 1b/2 clinical trials with Merck and Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Merck KGaA, Darmstadt, Germany and Pfizer Inc. in ovarian cancer. Syndax is also developing entinostat as a combination therapeutic in a Phase 3 clinical trial that is being conducted with ECOG-ACRIN for advanced hormone receptor positive breast cancer.